Becton, Dickinson and Company (BDX) Revenue by Segment

Becton, Dickinson and Company revenue by segment at a glance

In Q3 fiscal 2026 (the quarter ended June 30, 2026), Becton, Dickinson and Company's largest business segment was Medical Essentials, with $1.68 billion or 34% of revenue, up 4.6% from a year earlier. Next: Interventional (28%), Connected Care (25%) and BioPharma Systems (13%).

By region, United States brought in 62% and Non-US brought in 38% of revenue in Q3 fiscal 2026.

The fastest-growing business segment from a year earlier was BioPharma Systems (+6.5%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q1 fiscal 2018.

Becton, Dickinson and Company

BDXHealthcare

United States

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

Medical EssentialsLife SciencesInterventionalConnected CareBioPharma Systems

Q3 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before
Medical Essentials	USD 1.68B	33.6%	+4.6%
Interventional	USD 1.41B	28.4%	+6.5%
Connected Care	USD 1.22B	24.6%	+5.0%
BioPharma Systems	USD 670.00M	13.4%	+6.5%

Sum of items USD 4.98B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18
Medical Essentials	1.7B	1.6B	1.6B	–	1.6B	1.6B	1.6B	2.8B	2.6B	2.4B	2.2B	2.6B	2.4B	2.4B	2.2B	2.4B	2.2B	2.2B	2.1B	1.7B	2.1B	2.3B	2.3B	1.3B	2.1B	2.2B	2.1B	2.4B	2.3B	2.2B	2.1B	2.3B	2.2B	2.2B	1.9B
Life Sciences	–	–	766.0M	–	–	–	836.0M	1.3B	1.3B	1.3B	1.3B	1.3B	1.2B	1.3B	1.3B	1.3B	1.3B	1.5B	1.5B	1.5B	1.4B	1.6B	2.0B	1.5B	951.0M	1.1B	1.1B	1.1B	1.1B	1.1B	1.1B	1.1B	1.1B	1.1B	1.0B
Interventional	1.4B	1.4B	1.3B	–	1.3B	1.3B	1.3B	1.3B	1.2B	1.3B	1.2B	1.2B	1.2B	1.2B	1.1B	1.1B	1.1B	1.1B	1.1B	1.1B	1.1B	1.0B	1.1B	978.0M	782.0M	990.0M	1.0B	1.0B	981.0M	963.0M	970.0M	948.0M	954.0M	952.0M	183.0M
Connected Care	1.2B	1.1B	1.1B	–	1.2B	1.1B	1.1B	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
BioPharma Systems	670.0M	590.0M	429.0M	–	629.0M	575.0M	418.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Becton, Dickinson and Company revenue by business segment, last 4 quarters

Business segment	Q3 FY26	Q2 FY26	Q1 FY26	Q3 FY25	Share
Medical Essentials	$1.7B	$1.6B	$1.6B	$1.6B	34%
Interventional	$1.4B	$1.4B	$1.3B	$1.3B	28%
Connected Care	$1.2B	$1.1B	$1.1B	$1.2B	25%
BioPharma Systems	$670.0M	$590.0M	$429.0M	$629.0M	13%

In USD, fiscal quarters as reported; share = part of Q3 FY26 revenue.

Becton, Dickinson and Company revenue by region, last 4 quarters

Region	Q3 FY26	Q2 FY26	Q1 FY26	Q3 FY25	Share
United States	$3.1B	$2.9B	$3.2B	$2.9B	62%
Non-US	$1.9B	$1.8B	$2.1B	$1.8B	38%

In USD, fiscal quarters as reported; share = part of Q3 FY26 revenue.

Questions and answers

What are Becton, Dickinson and Company's business segments?

Medical Essentials, Interventional, Connected Care and BioPharma Systems (as reported for Q3 fiscal 2026).

Which business segment makes the most money for Becton, Dickinson and Company?

Medical Essentials: $1.68 billion, or 34% of revenue, in Q3 fiscal 2026.

Where does Becton, Dickinson and Company make its money?

By region in Q3 fiscal 2026: United States (62%) and Non-US (38%).

MoreBecton, Dickinson and Company stock overview Becton, Dickinson and Company financials Becton, Dickinson and Company executive team Becton, Dickinson and Company shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.